Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine Pathology
Published in: Endocrine Pathology 2/2012

01-06-2012

Occult Primary Medullary Thyroid Carcinoma Presenting with Pituitary and Parotid Metastases: Case Report and Review of the Literature

Authors: Andrea Conway, Andres Wiernik, Ajay Rawal, Cornelius Lam, Hector Mesa

Published in: Endocrine Pathology | Issue 2/2012

Login to get access

Excerpt

Medullary thyroid carcinoma (MTC) accounts for <10% of all thyroid malignancies and is derived from the calcitonin-producing C cell [1, 2]. It is of particular interest because of its association with hereditary syndromes, aggressiveness, and refractoriness to adjuvant therapies, and its association with mutations in the RET (rearranged during transfection) proto-oncogene, which encodes a receptor tyrosine kinase that may be amenable to therapy with the recently available tyrosine kinase inhibitors (TKI) [3, 4]. Thyroid tumors metastasizing to the pituitary and parotid gland are rare, and medullary thyroid carcinoma metastatic to either site has only been reported in a handful of instances. Here, we report a rare case of an occult MTC, which presented with clinical symptoms associated with synchronous metastases to the pituitary and parotid gland, and discuss its differential diagnosis. …
Literature
1.
2.
Mills, Stacy E. Pathology of the thyroid and parathyroid disease. In: Sternberg’s Diagnostic Surgical Pathology. 6th ed.
3.
Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. JAMA 276(19):1575-1579, 1996.PubMedCrossRef
4.
Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol 61:299–310, 2004.CrossRef
5.
DeLellis R.A., Lloyd R.V., Heitz, P.U., Eng C. (Eds.): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. IARC Press: Lyon 2004; 86–91.
6.
Grozinsky-Glasberg S, Benbassat CA, Tsvetov G, Feinmesser R, Peretz H, Shimon I, Lapidot M. Medullary thyroid cancer: a retrospective analysis of a cohort treated at a single tertiary care center between 1970 and 2005. Thyroid 17(6):549–556, 2007.PubMedCrossRef
7.
Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S, Schlumberger M. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 88(5):2070–2075, 2003.PubMedCrossRef
8.
Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 229(6):880–888, 1999.PubMedCrossRef
9.
Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS Jr, Hickey RC, Samaan NA. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 63(6):319–42, 1984.
10.
Machens A, Hauptmann S, Dralle H. Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World J Surg 31(10):1960–1965, 2007.PubMedCrossRef
11.
Quayle FJ, Moley JF. Medullary thyroid carcinoma: including MEN2A and 2B syndromes. J Surg Oncol 89:122–129, 2005.PubMedCrossRef
12.
Chen H, Sipper RS, O’Dorisio MS, Vinik Al, Lloyd RV, Pacak K; North American Neuroendocrine Tumor Society (NANETS). The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 39(6):775–783, 2010.PubMedCrossRef
13.
Albores-Saavedra J, LiVolsi VA, Williams ED. Medullary carcinoma. Semin Diagn Pathol 2:137–146, 1985.PubMed
14.
Sironi M, Cozzi L, Pareschi R, Spreafic GL, Assi A. Occult sporadic medullary microcarcinoma with lymph node metastases. Diagn Cytopathol 21(3):203–206, 1999.PubMedCrossRef
15.
Beressi N, Campos JM, Beressi JP, Franc B, Niccoli-Sire P, Conte-Devolx B, Murat A, Caron P, Baldet L, Kraimps JL, Cohen R, Bigorgne JC, Chabre O, Lecomte P, Modigliani E. Thyroid. Sporadic medullary microcarcinoma of the thyroid: a retrospective analysis of eighty cases. Thyroid 8(11):1039–1044, 1998.PubMedCrossRef
16.
Fassett DR, Couldwell WT. Metastasis to the pituitary gland. Neurosurg Focus 16(4):E8, 2004.PubMed
17.
Teears RJ, Silverman EM. Clinicopathologic review of 88 cases of carcinoma metastatic to the pituitary gland. Cancer 36:216–220, 1975.PubMedCrossRef
18.
Asa SL. Practical pituitary pathology: what does the pathologist need to know? Arch Pathol Lab Med 132:1231–1240, 2008.PubMed
19.
20.
Roessmann U, Kaufman B, and Friede RL. Metastatic lesions in the sella turcica and pituitary gland. Cancer 25:478–480, 1970.PubMedCrossRef
21.
Bhatoe HS, Badwal S, Dutta V, Kannan N. Pituitary metastasis from medullary carcinoma of thyroid: case report and review of literature. J Neurooncol 89:63–67, 2008.PubMedCrossRef
22.
Santarpia L, Gagel RF, Sherman SI, Sarlis NJ, Evans DB, Hoff AO. Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer. Head Neck 31(3): 419–423, 2009.PubMedCrossRef
23.
Batsakis JG. Pathology consultation. Parotid gland and its lymph nodes as metastatic sites. Ann Otol Rhinol Laryngol 92:209–210, 1983.PubMed
24.
Nuyens M, Schüpbach J, Stauffer E, Zbären P. Metastatic disease to the parotid gland. Otolaryngol Head Neck Surg 135:844–848, 2006.PubMedCrossRef
25.
Mohyuddin H, Mahrous A, Sharma V, Gluckman P. Parotid mass: an unusual presentation of gastroesophageal malignancy. J Laryngol Otol 125(5):546–548, 2011.PubMedCrossRef
26.
Ulubas B, Ozcan C, Polat A. Small cell lung cancer diagnosed with metastasis in parotid gland. J Craniofac Surg 21(3):781–783, 2010.PubMedCrossRef
27.
Moutaouakil A, Baha AT, and Amraoui A. Metastase choroidienne d’un carcinome de la thyroide (a propos d’un cas). Bull Soc Belge Ophtalmol 288:19–22, 2003.PubMed
28.
Pelosi S, Genden EM. Medullary thyroid carcinoma metastatic to the parotid gland. The Laryngoscope (Meeting Abstracts) 119(Supplement S3):S253, 2009.
29.
Ebert EC. The thyroid and the gut. J Clin Gastroenterol 44:402–406, 2010.PubMed
30.
Krafts KP, Pambuccian SE. Romanowsky staining in cytopathology: history, advantages and limitations. Biotech Histochem 86(2):82–93, 2011.PubMedCrossRef
31.
Agoff SN, Lamps LW, Philip AT, Amin MB, Schmidt RA, True LD, Folpe AL. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol 13(3):238–242, 2000.PubMedCrossRef
32.
Nonaka D, Tang Y, Chiriboga L, Rivera M, Ghossein R. Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol 21:192–200, 2008.PubMed
33.
Mills SE. Neuroectodermal neoplasms of the head and neck with emphasis on neuroendocrine carcinomas. Mod Pathol 15(3):264–278, 2002.PubMedCrossRef
34.
Wenig BM, Hyams VJ, Heffner DK. Moderately differentiated neuroendocrine carcinoma of the larynx. A clinicopathologic study of 54 cases. Cancer 62:2658–2676, 1988.PubMedCrossRef
35.
Machens A, Haedecke J, Hinze R, Thomusch O, Schneyer U, Dralle H. Hypercalcitoninemia in a sporadic asymptomatic neuroendocrine tumor of the pancreatic tail. Dig Surg 17(5):522–4, 2000.PubMedCrossRef
36.
Alapat DV, Ain KB, Sloan DA, Monaghan KG, Karabakhtsian RG. Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma. Endocrine 39(2):148-52, 2011.PubMedCrossRef
37.
Leboulleux S, Baudin E, Young J, Caillou B, Lazar V, Pellegriti G, Ducreux M, Schaison G, Schlumberger M. Gastroenteropancreatic neuroendocrine tumor metastases to the thyroid gland: differential diagnosis with medullary thyroid carcinoma. Eur J Endocrinol 140:187–191, 1999.PubMedCrossRef
38.
Milione M, Seregni E. Pathological diagnosis and tumor markers. Tumori 96: 810–816, 2010.PubMed
39.
Bajetta E, Ferrari L,Martinetti A, Celio L, Procopio G, Artale S, Zilembo N, Di Bartolomeo M, Seregni E, Bombardieri E. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 86: 858–865, 1999.PubMedCrossRef
40.
Rosai and Ackerman’s Surgical Pathology, 10th edn; 48, 329–330, 526–531, 822–840.
41.
Su CH, Chang H, Chen CJ, Liu LC, Wang HC, Lane HY, Bau DT. The carcinoembryonic antigen as a potential prognostic marker for neuroendocrine carcinoma of the breast. Anticancer Res 32(1):183–188, 2012.PubMed
42.
Kleinschmidt–DeMasters. Pituitary Gland. In: Rosai and Ackerman’s Surgical Pathology, 10th edn.
43.
Coons SW, Etrada SI, Gamez R, White WL. Cytokeratin CK7 and CK 20 expression in pituitary adenomas. Endocr Pathol 16: 201–210, 2005.PubMedCrossRef
44.
Lee EB, Tihan T, Scheithauer BW, Zhang PJ, Gonatas NK. Thyroid transcription factor 1 expression in sellar tumors: a histogenetic marker?. JNEN 68(5):482–8, 2009.
45.
Takei H, Goodman JC, Tanaka S, Bhattacharjee MB, Bahrami A Powell, SZ. Pituicytoma incidentally found at autopsy. Pathol Int 55:745–749, 2005.PubMedCrossRef
46.
Salame K, Ouaknine GE, Yossipov J, Rochkind S. Paraganglioma of the pituitary fossa: diagnosis and management. J Neurooncol 54(1):49–52, 2001.PubMedCrossRef
47.
McLaughlin DM, Gray WJ, Jones FG, Mirakhur M, McCance DR, Sheridan B, Atkinson AB. Plasmacytoma: an unusual cause of a pituitary mass lesion. A case report and a review of the literature. Pituitary 7(3):179–81, 2004.PubMedCrossRef
48.
Giraudet AL, Vanel D, Leboulleux S, Aupérin A, Dromain C, Chami L, Ny Tovo N, Lumbroso J, Lassau N, Bonniaud G, Hartl D, Travagli JP, Baudin E and Schlumberger M. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 92(11):4185–4190, 2007.PubMedCrossRef
49.
Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS Jr, Hickey RC, Samaan NA. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 63(6):319–342, 1984.
50.
O’Riordain DS, O’Brien T, Weaver AL, Gharib H, Hay ID, Grant CS, van Heerden JA. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery 116(6):1017–1023, 1994.PubMed
51.
Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88(5):1139–1148, 2000.PubMedCrossRef
52.
Samaan NA, Schultz PN, Hickey RC. Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab 67(4):801–805, 1988.PubMedCrossRef
53.
Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 6(4):305–310, 1996.PubMedCrossRef
54.
Nocera M, Baudin E, Pellegriti G, Cailleux AF, Mechelany-Corone C, Schlumberger M. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC). Br J Cancer 83(6):715–718, 2000.PubMedCrossRef
55.
Wu LT, Averbuch SD, Ball DW, de Bustros A, Baylin SB, McGuire WP 3rd. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 73(2):432–436, 1994.PubMedCrossRef
56.
Medley L, Morel AN, Farrugia D, Reed N, Hayward N, Davies JM, Kirichek O, Thakker RV, Talbot DC. Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. Br J Cancer 104(7):1067–1070, 2011.PubMedCrossRef
57.
Fürstenberger G, Schmid P, Duquesne A, Ammann M, Senn HJ. Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda) monotherapy. Cancer Chemother Pharmacol 61(2):347–348, 2008.PubMedCrossRef
58.
Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24(3):401–406, 2006.PubMedCrossRef
59.
Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M, Oberg K, Eriksson B, Skogseid B.Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13(10):2986–2991, 2007.PubMedCrossRef
60.
R. L. Fine, D. R. Fogelman, S. M. Schreibman. Effective Treatment of Neuroendocrine Tumors With Temozolomide and Capecitabine. Journal of Clinical Oncology (Meeting Abstracts) 23(Suppl 16S):4216, 2005.
61.
Paiva CE, Michelin OC. Use of capecitabine in refractory metastatic medullary thyroid carcinoma. Thyroid 18(5):587, 2008.PubMedCrossRef
62.
Gilliam LK, Kohn AD, Lalani T, Swanson PE, Vasko V, Patel A, Livingston RB, Pickett CA.Capecitabine therapy for refractory metastatic thyroid carcinoma: a case series. Thyroid 16(8):801–810, 2006.PubMedCrossRef
63.
Labidi SI, Gravis G, Tarpin C, Brun V, Viens P. Medullary thyroid cancer treated by capecitabine. Anticancer Drugs 18(7):831–834, 2007.PubMedCrossRef
64.
Eriksson B. New drugs in neuroendocrine tumors: rising of new therapeutic philosophies? Curr Opin Oncol 22(4):381–386, 2010.PubMedCrossRef
65.
66.
Zhang J, Yang PL, Gray NS.Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9(1):28–39, 2009.PubMedCrossRef
67.
Spector E, Franklin MJ, Truskinovsky AM, Dudek AZ. Sorafenib induces partial response in metastatic medullary thyroid carcinoma. Acta Oncol 49(1):104–106, 2010.PubMedCrossRef
68.
Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28(14):2323–2330, 2010.PubMedCrossRef
69.
Cohen, EEW, Needles, BM, Cullen, KJ, et al. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol (Meeting Abstracts) 26:6025, 2008.
70.
Ravaud, A, de la Fouchardière, C, Courbon, F, et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. J Clin Oncol (Meeting Abstracts) 26:6058, 2008.CrossRef
71.
Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27(23):3794–801, 2009.PubMedCrossRef
72.
Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28(5):767–72, 2010.PubMedCrossRef
Metadata
Title
Occult Primary Medullary Thyroid Carcinoma Presenting with Pituitary and Parotid Metastases: Case Report and Review of the Literature
Authors
Andrea Conway
Andres Wiernik
Ajay Rawal
Cornelius Lam
Hector Mesa
Publication date
01-06-2012
Publisher
Springer US
Published in
Endocrine Pathology / Issue 2/2012
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-012-9200-4

Other articles of this Issue 2/2012

Endocrine Pathology 2/2012 Go to the issue

Report

Images in Endocrine Pathology: Spindle Cell Lesion of the Thyroid Gland

ReviewPaper

Different Clonal Origin of Bilateral Papillary Thyroid Carcinoma, with a Review of the Literature

Report

Tumefactive Postmenopausal Gonadotroph Cell Hyperplasia

OriginalPaper

Expression and Clinical Significance of Wnt Players and Survivin in Pituitary Tumours

Report

Bilateral Adrenocortical Oncocytoma with Bilateral Myelolipomatous Metaplasia

OriginalPaper

Pathological Findings of Thyroid Nodules After Percutaneous Laser Ablation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits